Filing Flows › Carlsmed (CARL) › R&D spending
Carlsmed (CARL) R&D spending by quarter
Carlsmed's R&D spending was $6.0M in Q2 2026 (second quarter 2026), +17% from Q1 2026. Over the last 5 quarters it ranged from $4.2M (Q2 2025) to $6.0M (Q2 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $6.0M | +17% | +45% |
| Q1 2026 | $5.2M | -2% | — |
| Q4 2025 | $5.3M | +18% | — |
| Q3 2025 | $4.4M | +7% | — |
| Q2 2025 | $4.2M | — | — |
Q2 2026 at a glance
Carlsmed, Q2 2026: revenue $18.9M (+57% year over year), operating margin -58.3%, net loss $10.5M, operating cash flow −$7.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Carlsmed's R&D spending?
Carlsmed's R&D spending was $6.0M in Q2 2026 (second quarter 2026), +17% from Q1 2026.
How has Carlsmed's R&D spending changed?
Over the last 5 quarters it ranged from $4.2M (Q2 2025) to $6.0M (Q2 2026).